Yamaguchi et al. reported that an increase in the frequency of the CX3CR1+ subset in circulating CD8+ T cells early after ICI therapy correlated with response and survival in 36 NSCLC patients [77]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.